Citations

Showing 10 of 108104 citations.

Alcohol Withdrawal Syndrome in Women vs Men: Analysis of 1496 Cases at a Single Site
Girgla, Navkaran, Carlson, Richard W, Canales, Francisco J., Davis, Jesse, Emami, Maryam, Cooper, Tracy, Carlson, Richard W.

Mayo Clinic

American Journal of Critical Care | May 1, 2022 | Volume: 31 | Issue: 3 | Pages: 212-219

10.4037/ajcc2022616 | PMID 35466349 Get It

Background Studies of alcohol withdrawal syndrome indicate a higher prevalence in men than in women. However, it is unknown how the condition differs between the sexes. Objective To assess alcohol withdrawal syndrome in women versus men at a single site. Methods All cases of alcohol withdrawal syndrome at a public hospital from 2010 to 2014 were reviewed retrospectively. For all 1496 episodes, age, sex, and admission to a general care unit (ward) versus the medical intensive care unit were ascertained, along with patient survival. A detailed analysis was performed of 437 cases: all 239 patients admitted to the medical intensive care unit, all 99 female patients admitted to the ward, and 99 randomly selected male patients admitted to the ward. Also analyzed were administration of benzodiazepines, disease course, length of stay, and complications. Results Men accounted for 92% of all cases (1378 of 1496; P < .001) and medical intensive care unit admissions (220 of 239; P < .05). Sixteen percent of both men and women were admitted to the medical intensive care unit. Men were older (mean age, 45.6 vs 43.9 years; P < .01), and women required more benzodiazepines. Similar rates of complications occurred in both sexes, although women had a higher rate of pancreatitis and men had higher rates of pneumonia, higher rates of sepsis, and longer stays. Conclusions Men and women with alcohol withdrawal syndrome have similar complications, courses, and intensive care unit admission rates, although men are more prone to pneumonia and have longer stays.
Prospective Validation of Sedation Scale Scores That Identify Light Sedation: A Pilot Study
Brown, Caitlin S. , Marotta, Pasquale J., Riker, Richard R. , Eldridge, Ashley, May, Teresa , Fraser, Gilles L.

Mayo Clinic

American Journal of Critical Care | May 1, 2022 | Volume: 31 | Issue: 3 | Pages: 202-208

10.4037/ajcc2022437 | PMID 35466351 Get It

Background Intensive care unit (ICU) sedation guidelines recommend targeting a light sedation level, but light sedation has no accepted definition, and inconsistent levels have been proposed. Objective To determine Sedation-Agitation Scale and Richmond Agitation-Sedation Scale scores that best describe patients’ ability to follow voice commands. Methods This prospective, observational pilot study enrolled a convenience sample of ICU patients receiving mechanical ventilation. Pairs of trained investigators evaluated scores on the Sedation-Agitation Scale and Richmond Agitation-Sedation Scale and ability to follow commands before and up to 2 hours after sedation lightening in a blind, independent, simultaneous fashion. Positive predictive values (PPVs) and likelihood ratios (LRs) of Sedation-Agitation Scale and Richmond Agitation-Sedation Scale scores associated with light sedation (ability to follow at least 3 commands) were calculated. Results Ninety-six assessments (50 before and 46 after lightening of sedation) were performed in medical ICU patients. Scores best associated with ability to follow at least 3 commands were Sedation-Agitation Scale score of 4 (PPV, 0.88; 95% CI, 0.70-0.98; LR, 14.0) and Richmond Agitation-Sedation Scale score of −1 (PPV, 0.81; 95% CI, 0.61-0.93; LR, 10.7), superior to previously recommended thresholds of Sedation-Agitation Scale score of 3 (PPV, 0.62; 95% CI, 0.48-0.75; LR, 3.1) and Richmond Agitation-Sedation Scale score of −3 (PPV, 0.52; 95% CI, 0.39-0.64; LR, 2.0). Conclusions The level of sedation most associated with the ability to follow commands appears higher than previously recommended. Further study is needed regarding the effects of sedation level on ICU patients’ ability to follow commands and assessment of delirium, pain, and patient preferences.
Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk
Tian, Yu , Kim, Andre E. , Harrison, Tabitha A. , Carreras‐Torres, Robert , Díez‐Obrero, Virginia , Drew, David A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Obón‐Santacana, Mireia , Ose, Jennifer , Duijnhoven, Fränzel J.B. van , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Brenner, Hermann , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Harlid, Sophia , Hoffmeister, Michael , Joshi, Amit D. , Li, Li , Nan, Hongmei , Nassir, Rami , Prentice, Ross L. , Rennert, Gad , Slattery, Martha L. , Thibodeau, Stephen N. , Guelpen, Bethany Van , Visvanathan, Kala , White, Emily , Woods, Michael O. , Wu, Anna H. , Casey, Graham , Kundaje, Anshul , Pardamean, Bens , Thomas, Duncan C. , Tsilidis, Konstantinos K. , Peters, Ulrike , Gauderman, W. James, Chang‐Claude, Jenny , Carreras-Torres, Robert , Drew, David A , Huyghe, Jeroen R , Jordahl, Kristina M , Murphy, Neil , Ulrich, Cornelia M , Ose, Jennifer , Peoples, Anita R , Ruiz-Narvaez, Edward , van Duijnhoven, Fränzel J B , Arndt, Volker , Bishop, D Timothy , Brenner, Hermann , Buchanan, Daniel D , Figueiredo, Jane C , Gruber, Stephen B , Harlid, Sophia , Hoffmeister, Michael , Jenkins, Mark A , Larsson, Susanna C , Marchand, Loïc Le , Li, Li , Giles, Graham G , Milne, Roger L , Nassir, Rami , Ogino, Shuji , Budiarto, Arif , Platz, Elizabeth A. , Potter, John D , Sakoda, Lori C , Schoen, Robert E , Slattery, Martha L , Van Guelpen, Bethany , Visvanathan, Kala , Wolk, Alicja , Wu, Anna H. , Kundaje, Anshul , Moreno, Victor , Pardamean, Bens , Thomas, Duncan C , Tsilidis, Konstantinos K , Chang-Claude, Jenny , Rennert, Gad , Harrison, Tabitha A , Tian, Yu , Nan, Hongmei , Obón-Santacana, Mireia , Diez-Obrero, Virginia , Bien, Stephanie A. , Lin, Yi , Qu, Conghui , Dimou, Niki , Hidaka, Akihisa , Morrison, John L. , Murphy, Neil , Ulrich, Cornelia M. , Shcherbina, Anna , Stern, Mariana Carla , Su, Yu-Ru , Arndt, Volker , Buchanan, Daniel D. , Chan, Andrew T. , Jenkins, Mark A. , Keku, Temitope O , Larsson, Susanna C. , Marchand, Loı̈c Le , Giles, Graham G. , Milne, Roger L. , Potter, John D. , Sakoda, Lori C. , Schoen, Robert E. , Wolk, Alicja , Campbell, Peter T. , Conti, David V. , Gunter, Marc J. , Lewinger, Juan Pablo , Moreno, Vı́ctor , Newcomb, Polly A. , Hsu, Li

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2022 | Volume: 114 | Issue: 8 | Pages: 1135-1148

10.1093/jnci/djac094 | PMID 35512400 Get It

Abstract Background The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk. Methods We conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants without CRC) from 38 studies, using logistic regression, 2-step method, and 2– or 3–degree-of-freedom joint test. A set-based score test was applied for rare genetic variants. Results The use of any MHT, estrogen only and estrogen-progestogen were associated with a reduced CRC risk (odds ratio [OR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.78; OR = 0.65, 95% CI = 0.53 to 0.79; and OR = 0.73, 95% CI = 0.59 to 0.90, respectively). The 2-step method identified a statistically significant interaction between a GRIN2B variant rs117868593 and MHT use, whereby MHT-associated CRC risk was statistically significantly reduced in women with the GG genotype (OR = 0.68, 95% CI = 0.64 to 0.72) but not within strata of GC or CC genotypes. A statistically significant interaction between a DCBLD1 intronic variant at 6q22.1 (rs10782186) and MHT use was identified by the 2–degree-of-freedom joint test. The MHT-associated CRC risk was reduced with increasing number of rs10782186-C alleles, showing odds ratios of 0.78 (95% CI = 0.70 to 0.87) for TT, 0.68 (95% CI = 0.63 to 0.73) for TC, and 0.66 (95% CI = 0.60 to 0.74) for CC genotypes. In addition, 5 genes in rare variant analysis showed suggestive interactions with MHT (2-sided P < 1.2 × 10−4). Conclusion Genetic variants that modify the association between MHT and CRC risk were identified, offering new insights into pathways of CRC carcinogenesis and potential mechanisms involved.
Addressing malnutrition and food insecurity with breadfruit in a rural, developing country: a case study and lessons learned in Thomassique, Haiti
Klyver, John M. , Haugen, Inga , Schulz, Logan, LaPais, Wiscard-Kardin, Saint-Fleur, Charles, Starke, Samuel J. , Piersaint, Jason, Rizzo, Anael, Sarazen, Kyra M

Mayo Clinic

Journal of Global Health Reports | April 30, 2022 | Volume: 6 | Issue: No issue available | Pages: No page available

10.29392/001c.34233 Get It

Haiti’s Central Plateau region suffers from significant malnutrition, economic hardship, and a crisis level of food insecurity. Already the poorest country in the Western Hemisphere in terms of gross domestic product (GDP) per capita, Haiti has pervasively high malnutrition rates, but the Central Plateau is among the most severely affected areas. One in five children of the Central Plateau suffers from malnutrition, and the region exhibits a devastating 30% rate of child stunting. Our US-based team affiliated with Klinik Sen Jozèf, a community-respected medical clinic in the Central Plateau city of Thomassique. We partnered with local Haitian leadership, a local agronomist, and Trees That Feed Foundation to introduce breadfruit (Artocarpus altilis) and an innovative development model to combat local malnutrition. Five years into the program, we have partnered with 152 farmers, and we have enhanced our malnutrition program with breadfruit derivatives. This report addresses the lessons we learned to assist others looking to introduce models or crops in a similar manner. Our experience is particularly significant in light of the COVID-19 pandemic, as supply chain disruptions have worsened food insecurity for more than 800 million people in low-income countries.
Multimodality Deep Phenotyping Methods to Assess Mechanisms of Poor Right Ventricular–Pulmonary Artery Coupling
Raza, Farhan , Kozitza, Callyn , Lechuga, Chris G, Seiter, Daniel, Merchant, Mohammed, Dharmavaram, Naga , Eldridge, Marlowe W. , Wieben, Oliver , Wieben, Oliver , Raza, Farhan , Corrado, Philip A. , Korcarz, Claudia E. , François, Christopher J. , Chesler, Naomi C.

Mayo Clinic

Function | April 30, 2022 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/function/zqac022 | PMID 35774590 Get It

Abstract Deep phenotyping of pulmonary hypertension (PH) with multimodal diagnostic exercise interventions can lead to early focused therapeutic interventions. Herein, we report methods to simultaneously assess pulmonary impedance, differential biventricular myocardial strain, and right ventricular:pulmonary arterial (RV:PA) uncoupling during exercise, which we pilot in subjects with suspected PH. As proof-of-concept, we show that four subjects with different diagnoses [pulmonary arterial hypertension (PAH); chronic thromboembolic disease (CTEPH); PH due to heart failure with preserved ejection fraction (PH-HFpEF); and noncardiac dyspnea (NCD)] have distinct patterns of response to exercise. RV:PA coupling assessment with exercise was highest-to-lowest in this order: PAH > CTEPH > PH-HFpEF > NCD. Input impedance (Z0) with exercise was highest in precapillary PH (PAH, CTEPH), followed by PH-HFpEF and NCD. Characteristic impedance (ZC) tended to decline with exercise, except for the PH-HFpEF subject (initial Zc increase at moderate workload with subsequent decrease at higher workload with augmentation in cardiac output). Differential myocardial strain was normal in PAH, CTEPH, and NCD subjects and lower in the PH-HFpEF subject in the interventricular septum. The combination of these metrics allowed novel insights into mechanisms of RV:PA uncoupling. For example, while the PH-HFpEF subject had hemodynamics comparable to the NCD subject at rest, with exercise coupling dropped precipitously, which can be attributed (by decreased myocardial strain of interventricular septum) to poor support from the left ventricle (LV). We conclude that this deep phenotyping approach may distinguish afterload sensitive vs. LV-dependent mechanisms of RV:PA uncoupling in PH, which may lead to novel therapeutically relevant insights.
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
Parrondo, Ricardo , Moustafa, Muhamad Alhaj , LaPlant, Betsy, Alegria, Victoria R., Chapin, Dustin, Sher, Taimur , Paulus, Aneel , Chanan‐Khan, Asher , Parrondo, Ricardo D , Moustafa, Muhamad Alhaj , LaPlant, Betsy R, Alegria, Victoria, Chanan-Khan, Asher A., Paulus, Aneel , Ailawadhi, Sikander , Roy, Vivek

Mayo Clinic

Hematological Oncology | April 30, 2022 | Volume: 40 | Issue: 4 | Pages: 695-703

10.1002/hon.3012 | PMID 35488778 Get It

Abstract Therapeutic strategies that target novel pathways are urgently needed for patients with relapsed/refractory multiple myeloma (RRMM). Ibrutinib is an oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in MM cells. This phase 1 dose‐escalation study examined various doses of ibrutinib in combination with standard doses of lenalidomide (25 mg) and dexamethasone (40 mg) using a standard 3 + 3 design in RRMM patients. The primary objective was to determine the maximum tolerated dose (MTD) of ibrutinib in combination with lenalidomide and dexamethasone. Patients ( n = 15) had received a median of 4 prior regimens, 53% were triple‐class exposed, 33% were penta‐exposed, and 54% were lenalidomide‐refractory. The MTD of ibrutinib was 840 mg ( n = 6) and only 1 dose‐limiting toxicity; a grade 3 rash possibly related to ibrutinib was noted. The most common ≥ grade 3 adverse events were rash in 2 (13%), lymphopenia in 2 (13%), leukopenia, neutropenia, thrombocytopenia, and anemia all occurring in 3 (20%) patients each. One patient achieved a partial response for an overall response rate of 7%. The clinical benefit rate was 80%. The median time to progression was 3.8 months. Ibrutinib, lenalidomide and dexamethasone appears to be a safe and well‐tolerated regimen with reasonable efficacy in heavily pretreated RRMM patients.
Analytical Validation of GFRNMR: A Blood-Based Multiple Biomarker Assay for Accurate Estimation of Glomerular Filtration Rate
Fuhrmann, Markus, Santamaría, Amauri Schwäble , Scott, Renee, Meeusen, Jeffrey W. , Fernandes, Marianna, Venz, John, Rothe, Victoria, Stämmler, Frank , Ehrich, J. H. H. , Schiffer, Eric, Schwäble Santamaria, Amauri , Venz, John

Mayo Clinic

Diagnostics | April 30, 2022 | Volume: 12 | Issue: 5 | Pages: 1120

10.3390/diagnostics12051120 | PMID 35626276 Get It

Accurate and precise monitoring of kidney function is critical for a timely and reliable diagnosis of chronic kidney disease (CKD). The determination of kidney function usually involves the estimation of the glomerular filtration rate (eGFR). We recently reported the clinical performance of a new eGFR equation (GFRNMR) based on the nuclear magnetic resonance (NMR) measurement of serum myo-inositol, valine, and creatinine, in addition to the immunoturbidometric quantification of serum cystatin C, age and sex. We now describe the analytical performance evaluation of GFRNMR according to the Clinical and Laboratory Standards Institute guidelines. Within-laboratory coefficients of variation (CV%) of the GFRNMR equation did not exceed 4.3%, with a maximum CV% for repeatability of 3.7%. Between-site reproducibility (three sites) demonstrated a maximum CV% of 5.9%. GFRNMR stability was demonstrated for sera stored for up to 8 days at 2–10°C and for NMR samples stored for up to 10 days in the NMR device at 6 ± 2°C. Substance interference was limited to 4/40 (10.0%) of the investigated substances, resulting in an underestimated GFRNMR (for glucose and metformin) or a loss of results (for naproxen and ribavirin) for concentrations twice as high as usual clinical doses. The analytical performances of GFRNMR, combined with its previously reported clinical performance, support the potential integration of this NMR method into clinical practice.
Intra-procedural cerebral sinus thrombosis during endovascular treatment of idiopathic intracranial hypertension
Larco, Jorge Arturo , Abbasi, Mehdi , Kadirvel, Ramanathan , Kallmes, David F. , Brinjikji, Waleed , Arturo Larco, Jorge L , Savastano, Luis

Mayo Clinic

The Neuroradiology Journal | April 30, 2022 | Volume: 35 | Issue: 5 | Pages: 654-657

10.1177/19714009221096837 | PMID 35488380 Get It

Stenting of the intracranial venous sinuses has shown promising results in patients who are refractory to medical treatment of idiopathic intracranial hypertension (IIH). Among the reported complications associated with this procedure, in-stent thrombosis is an unreported one. We present a case of cerebral sinus thrombosis during endovascular treatment of IIH. A 33-year-old man with multiple comorbidities was presented with non-specific vision changes and headaches. Initial workup revealed a diagnosis of idiopathic intracranial hypertension which was treated medically but with no improvement. Therefore, cerebral sinus stenting was pursued. During the procedure, an in-stent thrombus was identified which was retrieved mechanically and was sent for histological and immunohistochemical evaluation. The retrieved thrombus was predominantly composed of RBCs (57.8%) followed by fibrin (30.78%), platelet (6.4%), and WBCs (5.95%), with high expression of CitH3 (neutrophil extra cellular traps specific marker) (10.9%), and CD66 (11.35%).
What's JAK'ing Up the Risk of Cancer and Thromboembolism?
Houghton, Damon E.

Mayo Clinic

The Hematologist | April 30, 2022 | Volume: 19 | Issue: 3 | Pages: No page available

10.1182/hem.v19.3.202232 Get It

Methodological Approach to Improve Surgical Outcomes of a Pig Subretinal Implantation Model
Mano, Fukutaro , Gandhi, Jarel K. , Silva, Raphael Pereira da, Silva, Aline Do Amaral, Iezzi, Lucas, Iezzi, Raymond , Pulido, José S. , Marmorstein, Alan D. , da Silva, Raphael Pereira, Marmorstein, Alan D

Mayo Clinic

Translational Vision Science & Technology | April 29, 2022 | Volume: 11 | Issue: 4 | Pages: 24

10.1167/tvst.11.4.24 | PMID 35486039 Get It